HEARTFLOW Stock Price, News & Analysis

Heartflow, Inc. (Nasdaq: HTFL) is a commercial-stage medical technology company in the healthcare sector that focuses on health information services for coronary artery disease (CAD). The company states that it has pioneered the use of software and artificial intelligence (AI) to deliver non-invasive solutions for diagnosing and managing CAD, which is described as the world’s leading cause of death. Heartflow operates and manages its business as a single reportable segment centered on non-invasive coronary artery disease detection solutions.

According to company disclosures, Heartflow’s technology is built around the Heartflow One platform, which uses AI to turn coronary computed tomography angiography (CTA) scans into personalized 3D models of the heart. These models are designed to provide clinically meaningful, actionable insights into plaque location, volume, and composition and the effect of plaque on blood flow, without the need for invasive procedures. The company describes its approach as redefining precision cardiovascular care by enabling earlier detection, more accurate diagnosis, and long-term management of CAD.

Core solutions and clinical focus

Heartflow reports that it offers AI-driven analyses derived from coronary CTA, including Heartflow FFRCT Analysis, Heartflow Plaque Analysis, and related capabilities within the Heartflow One platform. FFRCT Analysis is described in company communications as a noninvasive fractional flow reserve assessment that helps evaluate lesion-specific physiology and guide diagnostic decision-making. Heartflow Plaque Analysis is characterized as an FDA-cleared, AI-powered plaque quantification tool that measures plaque burden and composition and has 95% agreement with intravascular ultrasound (IVUS) in blinded core lab adjudication, based on cited research.

The company highlights that Heartflow Plaque Analysis can support quantitative coronary plaque assessment, risk stratification, and personalized treatment planning for patients with suspected or established CAD. In its own materials, Heartflow notes that the American College of Cardiology (ACC) and American Heart Association (AHA) scientific statements emphasize the importance of quantitative plaque analysis and recognize plaque burden and composition as central to managing nonobstructive CAD. Heartflow positions its Plaque Analysis as aligned with these recommendations by combining AI-driven analysis with expert quality review and standardized reporting.

Data foundation and validation

Heartflow states that its technology is supported by what it describes as the world’s largest coronary imaging dataset and a proprietary data pipeline built from more than 100 million annotated CTA scans. This data foundation is used to train advanced AI models intended to deliver accurate and reproducible insights across diverse patient populations. The company reports that its AI-driven solutions have been validated through clinical evidence in over 100 studies assessing hundreds of thousands of patients, and that its work is backed by ACC/AHA guidelines and more than 600 peer-reviewed publications.

In multiple company releases, Heartflow notes that its coronary CTA acceptance rates exceed 96%, and in some instances 97%, in real-world practice. The company also references large-scale studies and registries, such as the FISH&CHIPS study conducted within England’s National Health Service and the DECIDE registry, as sources of real-world evidence. These analyses are described as demonstrating prognostic value, changes in medical management when Heartflow Plaque Analysis is added to CTA alone, and system-level cost savings when FFRCT Analysis is integrated into diagnostic pathways.

Clinical integration and workflow

Heartflow emphasizes that its analyses are designed to integrate into existing clinical workflows. Company materials state that Heartflow delivers final, quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay. This integrated workflow is presented as supporting both outpatient and health-system settings by reducing unnecessary tests, guiding appropriate revascularization, and enabling earlier preventive treatment decisions.

The company also describes the introduction of Heartflow PCI Navigator as part of the Heartflow One platform. PCI Navigator is characterized as an AI-driven percutaneous coronary intervention (PCI) planning tool that provides interventional cardiologists with a patient-specific 3D model detailing anatomy, plaque composition, lesion-specific physiology, and information relevant to potential stent placement. According to Heartflow, PCI Navigator is intended to bring together lesion-specific FFRCT values, stenosis, plaque characteristics, and vessel territory information in a single view to support pre-procedural planning.

Regulatory and security posture

In its public statements, Heartflow notes that Heartflow Plaque Analysis is an FDA-cleared device, while Heartflow Plaque Staging is described as an investigational-only framework whose safety and effectiveness have not been reviewed by the U.S. Food and Drug Administration. The company also highlights adherence to multiple quality and security standards, stating that its quality system, global security, and patient-data integrity practices meet or exceed standards such as HITRUST, SOC 2 Type 2, ISO 13485, and ISO 27001, and in some disclosures also referencing compliance with regulations including GDPR, HIPAA, and CCPA.

Market presence and reimbursement

Heartflow reports that its technology has been adopted by more than 1,400 institutions globally and that clinicians have used its platform to help manage care for hundreds of thousands of patients worldwide. The company notes that it operates in the United States, the United Kingdom, Japan, and the rest of Europe, with the United States representing its largest source of revenue. Heartflow also highlights payer coverage developments, stating that Heartflow Plaque Analysis is covered by major U.S. commercial insurers and Medicare, with Aetna, Humana, Cigna, and UnitedHealthcare cited as examples of payers that have updated policies to align with radiology benefit manager guidance.

In addition, Heartflow points to the implementation of a Category I Current Procedural Terminology (CPT) payment code (75577) for Heartflow Plaque Analysis, which it describes as supporting reimbursement and broader adoption. The company characterizes these coverage and coding milestones as expanding access to AI-driven plaque analysis for patients with acute or stable chest pain and mild-to-moderate coronary artery narrowing identified on coronary CTA.

Business structure and exchange listing

Heartflow, Inc. is based in Mountain View, California, and is listed on the Nasdaq Global Select Market under the ticker symbol HTFL. SEC filings describe Heartflow as an emerging growth company. The company has disclosed that it completed an initial public offering and that it subsequently repaid and terminated a prior credit agreement, as detailed in its Form 8-K filings. Heartflow continues to report its financial condition and results of operations through periodic SEC reports and related press releases.

Risk considerations

In its own forward-looking statements and risk factor summaries, Heartflow notes that its business depends heavily on the success and adoption of its core products, including Heartflow FFRCT Analysis and Heartflow Plaque Analysis. The company cites risks such as the potential reluctance of healthcare providers to change standard diagnostic practices, dependence on third-party payer coverage and reimbursement, competition in an environment of rapid technological change, and regulatory requirements associated with medical devices and AI-based technologies. These risks are further described in Heartflow’s SEC filings and related investor materials.